Pancreatic Cancer Research

ResearcherThe University of Texas at AustinActive in the last 2 years

Craig D. Logsdon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2214-1491; OpenAlex author ID A5028009560; NIH RePORTER profile ID 1877254. Sources: OpenAlex.

Their work

Papers
38 (first author 0, last author 8)
Trials
0
Grants
3
Labs led
2
Collaborators
126
Papers, trials and grants by year

2011: 3 papers · 2012: 8 papers · 2013: 8 papers · 2014: 3 papers, 1 grant · 2015: 2 papers · 2016: 2 papers · 2017: 3 papers, 1 grant · 2018: 2 papers · 2019: 1 grant · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 2 papers

Papers 38

  1. Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation. Co-author DOI 10.1016/j.canlet.2024.216694↗
  2. Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.111085↗
  3. Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14112723↗
  4. Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo. Co-author DOI 10.1016/j.pan.2020.12.008↗
  5. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Co-author DOI 10.1038/s41374-020-00490-5↗
  6. Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer Co-author DOI 10.1038/s41374-021-00615-4↗
  7. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer. Co-author DOI 10.1074/jbc.ra119.012186↗
  8. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  9. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/scitranslmed.aat3487↗
  10. RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer. Last author DOI 10.1016/j.bbrc.2017.08.147↗
  11. Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53. Last author DOI 10.1038/onc.2016.461↗
  12. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1986↗
  13. TM4SF1 Regulates Pancreatic Cancer Migration and Invasion In Vitro and In Vivo. Last author DOI 10.1159/000445664↗
  14. The Significance of Ras Activity in Pancreatic Cancer Initiation. Co-author DOI 10.7150/ijbs.15020↗
  15. Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics. Co-author DOI 10.1152/ajpgi.00169.2015↗
  16. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo. Last author DOI 10.1371/journal.pone.0144969↗
  17. Preliminary evaluation of 1'-[(18)F]fluoroethyl-β-D-lactose ([(18)F]FEL) for detection of pancreatic cancer in nude mouse orthotopic xenografts. Co-author DOI 10.1016/j.nucmedbio.2014.08.001↗
  18. Targeting pancreatic ductal adenocarcinoma acidic microenvironment. Last author DOI 10.1038/srep04410↗
  19. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-14-0028↗
  20. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. Co-author DOI 10.1002/emmm.201302507↗
  21. Study human pancreatic cancer in mice: how close are they? Co-author DOI 10.1016/j.bbcan.2012.11.001↗
  22. Pancreatic cancer-associated Cathepsin E as a drug activator. Co-author DOI 10.1016/j.jconrel.2013.02.007↗
  23. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1053/j.gastro.2013.08.018↗
  24. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-4479↗
  25. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Last author DOI 10.1158/1535-7163.mct-12-0771↗
  26. Dietary energy balance modulation of Kras- and Ink4a/Arf+/--driven pancreatic cancer: the role of insulin-like growth factor-I. Co-author DOI 10.1158/1940-6207.capr-13-0185↗
  27. Plectin-1 Targeted AAV Vector for the Molecular Imaging of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2013.00084↗
  28. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Co-author DOI 10.1053/j.gastro.2012.08.044↗
  29. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Last author DOI 10.1136/gutjnl-2011-300544↗
  30. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Co-author DOI 10.1158/0008-5472.can-11-3102↗
  31. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. Co-author DOI 10.1158/1541-7786.mcr-12-0022↗
  32. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. Co-author DOI 10.1186/1756-8722-5-15↗
  33. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Co-author DOI 10.1245/s10434-011-1839-4↗
  34. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0040420↗
  35. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. Co-author DOI 10.1371/journal.pone.0042699↗
  36. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.25483↗
  37. Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. Last author DOI 10.1097/mpa.0b013e31821f6927↗
  38. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-11-0607↗

Grants 3

  1. Mechanisms of Alcohol Initiation of Chronic Pancreatic Diseases R21AA026462↗
  2. Highly Specific and Efficient Vectors for Targeting Pancreatic Cancer R01CA168712↗
  3. Texas Center for Cancer Nanomedicine U54CA151668↗

Closest collaborators

The 25 strongest of 126 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thiruvengadam Arumugam · 14 shared papers, 2011–2021 · strength 0.68
  2. Baoan Ji · 9 shared papers, 2011–2024 · strength 0.58
  3. Huamin Wang · 12 shared papers, 2011–2020 · strength 0.51
  4. Weiqin Lu · 3 shared papers, 2016–2024 · strength 0.47
  5. Anirban Maitra · 5 shared papers, 2017–2021 · strength 0.47
  6. Vijaya Ramachandran · 9 shared papers, 2011–2018 · strength 0.41
  7. Raghu Kalluri · 1 shared grant, 2019 · strength 0.40
  8. Zobeida Cruz‐Monserrate · 8 shared papers, 2012–2018 · strength 0.36
  9. Yongde Luo · 2 shared papers, 2022–2024 · strength 0.35
  10. Jianjia Ma · 2 shared papers, 2022–2024 · strength 0.35
  11. Ying Ma · 4 shared papers, 2011–2024 · strength 0.33
  12. James L. Abbruzzese · 5 shared papers, 2011–2022 · strength 0.28
  13. Rosa F. Hwang · 7 shared papers, 2011–2018 · strength 0.28
  14. Patrick Hwu · 3 shared papers, 2011–2024 · strength 0.28
  15. Brent A French · 1 shared paper, 1 shared grant, 2013–2017 · strength 0.27
  16. Kimberly A. Kelly · 1 shared paper, 1 shared grant, 2013–2017 · strength 0.27
  17. Mamoun Younes · 2 shared papers, 2021 · strength 0.24
  18. Kanchan Singh · 2 shared papers, 2021 · strength 0.24
  19. Sushovan Guha · 2 shared papers, 2021 · strength 0.24
  20. Nirav C Thosani · 2 shared papers, 2021 · strength 0.24
  21. Florencia M. McAllister · 2 shared papers, 2021 · strength 0.24
  22. Jennifer M. Bailey · 2 shared papers, 2021 · strength 0.24
  23. Huamin Wang · 1 shared paper, 2024 · strength 0.22
  24. Xiangqin Zhao · 1 shared paper, 2024 · strength 0.22
  25. Haojie Huang · 2 shared papers, 2017–2021 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.